GLP-1 Cholesterol Effects: What Happens to LDL, HDL, and Triglycerides?

Disclosure: The RX Index may earn a commission from one sponsored link near the end of this page. No medication is paid to appear or favored anywhere in the medical sections. Nothing you're about to read changes based on who pays us.

GLP-1 cholesterol effects are real, but they're uneven — and not in the direction most people expect. Triglycerides move the most in the six obesity-trial rows we examined. LDL barely moves at all. Across pooled placebo-controlled trials, the average LDL difference was about 3 mg/dL lower. In six selected trial rows from four current FDA prescribing-information documents, LDL ranged from 1.3% higher than placebo to 5.5% lower, while triglycerides were 7.1% to 24.9% lower than placebo. No GLP-1 or GIP/GLP-1 medicine is FDA-approved to treat high cholesterol, and none of them replaces a statin.

Your own result can land outside those trial averages depending on which medicine you take, what dose, where your numbers started, whether you have diabetes, whether a statin or another medicine changed, what you ate before the blood draw, and whether your weight is still dropping right now.

Here's the part almost nobody tells you, and it's the reason this page exists. Most articles report the before and after numbers from the treatment group. Very few show what happened to the placebo group — the people in the same trial who got an inactive look-alike treatment and the same background lifestyle program. When you put both groups side by side, a lot of the "GLP-1s improve your cholesterol" story gets much smaller. One number in particular shrinks from a 9.6% rise to a simple 1.5-percentage-point gap.

We'll show you which one.

Is this page for you?

Skip this page if: your LDL is 190 mg/dL or higher and high LDL is your only reason for looking at a GLP-1. A GLP-1 will not fix that number. Contact the clinician who ordered the test promptly. Your conversation is about LDL-lowering treatment, often including statins, and it's with your clinician — not a website. We say more about that below.

Do not stop or change a GLP-1, a statin, or any other prescription because of an article or one lab result. That includes this article.

Quick definitions, so the rest of this makes sense

We'll use these words a lot. Here's what each one means in plain terms.

• GLP-1 medicine. A drug that copies a gut hormone your body already makes. It changes hunger, digestion speed, and blood sugar. Wegovy, Ozempic, Saxenda, and Foundayo are all in this family.
• GIP/GLP-1 medicine. Zepbound and Mounjaro (tirzepatide) work on two hormone receptors instead of one. Related, but not the same class. That matters later.
• Lipid panel. A blood test that usually reports total cholesterol, LDL, HDL, and triglycerides.
• LDL. Carries cholesterol through your bloodstream. Too much can build up in artery walls. When doctors say they want your cholesterol lower, this is usually the number they mean.
• HDL. Helps carry cholesterol back toward the liver. Higher is generally better — but a good HDL number on its own doesn't cancel out other risks.
• Triglycerides. A type of fat in your blood. Moves a lot with food, alcohol, weight, and blood sugar.
• Total cholesterol. A combined number built mainly from LDL, HDL, and part of your triglyceride level. It can hide the fact that two numbers moved in opposite directions.
• Placebo. An inactive look-alike treatment given to one group in a trial so researchers can compare it with the active drug.
• Statin. A cholesterol drug — atorvastatin, rosuvastatin, simvastatin. Its main job is lowering LDL.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Do GLP-1 medicines lower cholesterol?

Answer: Yes, on average, but the effect is small and not the same across all four cholesterol numbers. A pooled analysis of placebo-controlled trials found GLP-1 receptor agonists lowered LDL cholesterol by about 2.93 mg/dL and total cholesterol by roughly 7 mg/dL. It did not find a statistically significant class-wide change in triglycerides, VLDL, or HDL. No GLP-1 medicine is FDA-approved to treat high cholesterol.

Let's put that LDL number in real terms, because percentages make it sound bigger than it is.

2.93 mg/dL. That's about three points.

An average difference of 2.93 points is like an LDL of 140 landing near 137, or an LDL of 110 landing near 107. That is an illustration, not a promise about your result. The number comes from placebo-controlled trials published in Volume 41, Issue 1 of Current Medical Research and Opinion, pooling studies of semaglutide, liraglutide, and dulaglutide. The finding was statistically real — meaning it's probably not just noise — but it is not large.¹

The same analysis found something else worth knowing. Across all those pooled trials:

• Triglycerides did not change by a statistically significant amount
• VLDL cholesterol did not change by a statistically significant amount
• HDL did not go up by a statistically significant amount
• And how much weight someone lost did not predict their LDL change

That last one surprises people. You'd assume losing 40 pounds drives your LDL down. In that pooled data, it didn't reliably do so.

Now hold that thought, because the FDA labels for the newer obesity drugs tell a partly different story — and we're going to show you both and explain why they disagree. That's the honest version. Most pages pick whichever set makes the drugs look better.

What the drugmaker itself says

Printed directly beneath Novo Nordisk's own lipid data for Wegovy, on its materials for doctors:

"Wegovy is not indicated to treat hypertension, type 2 diabetes, or dyslipidemia."²

Dyslipidemia means abnormal blood fats, including cholesterol. The company that makes the drug is telling prescribers it is not a cholesterol treatment. We think that's the single most useful sentence on this whole subject, and almost nobody quotes it.

What do current FDA labels show about GLP-1 cholesterol effects?

Answer: Current U.S. prescribing information shows meaningfully different lipid changes across products, doses, and trials. In six selected obesity-trial rows, LDL ranged from 1.3% higher than placebo to 5.5% lower, while triglycerides ranged from 7.1% to 24.9% lower than placebo. In every selected row, the triglyceride difference was larger than the LDL difference.

This is the part you can't get anywhere else in one place, so let's explain how we built it before you read it.

The RX Index GLP-1 Lipid Change Atlas — 2026

How we made this table. We opened four current U.S. prescribing-information documents covering Saxenda, Wegovy injection and tablets, Wegovy HD, Foundayo, and Zepbound. For each formulation or product, we picked one adult trial in people with obesity or overweight, preferring a population without type 2 diabetes when the label offered one. We used the highest labeled maintenance dose and an endpoint between 56 and 72 weeks, so the time frames are roughly comparable. Then we recorded what the label reports as the difference compared with placebo — not just the change from where people started.³⁴⁵⁶

What "compared with placebo" means. If LDL was 3.8% lower than placebo, that does not mean everyone's LDL dropped 3.8%. It means the label's analysis estimated that the treatment group ended up 3.8% lower than the placebo group. Both groups could have changed.

Reading the table: a negative number for total cholesterol, LDL, or triglycerides means the marker was lower than placebo — good. A positive HDL number means HDL was higher — good. A positive LDL number means LDL did not improve compared with placebo.

Sources: current U.S. prescribing information, checked August 8, 2026.³⁴⁵⁶ These are six separate trial rows with different participants, not a head-to-head comparison. Several labels say these cardiometabolic outcomes were supportive or exploratory and were not part of the trial's main statistical testing plan.

What is original here: the source numbers belong to the FDA labels and manufacturers. The trial selection, common format, placebo-relative comparison, and six-row Atlas are The RX Index's own analysis.

Four things this table shows that no single label does

1. LDL barely moved, and once it went the wrong way. Across all six rows, LDL landed somewhere between 1.3% higher than placebo and 5.5% lower. That is not a cholesterol drug's performance. A high-intensity statin lowers LDL by 50% or more.⁷

2. Triglycerides beat LDL in every single selected row. Every one. Saxenda's triglyceride number (−7.1%) is almost triple its LDL number (−2.4%). Zepbound's (−24.9%) is more than four times its LDL number (−5.5%). This is the clearest pattern in the entire dataset. If you only remember one thing from this page, make it this: in these six obesity-trial rows, triglycerides are the number that moves.

3. The highest FDA-approved weekly semaglutide injection dose for weight reduction did not lower LDL against placebo. Look at the Wegovy HD row. Total cholesterol was 0.6% higher than placebo. LDL was 1.3% higher. In that same trial, triglycerides were 15.4% lower and HDL was 10.1% higher.

More drug did not mean better LDL in that trial. It meant a slightly worse placebo-relative LDL result, alongside a big triglyceride win.

That does not mean every person taking Wegovy HD will have higher LDL. It means the label's group-level analysis did not show an LDL win against placebo in that trial.

4. Zepbound had the biggest numbers — and that still doesn't crown it. Zepbound's row is the strongest on total cholesterol, LDL, and triglycerides. We are not going to call it "best for cholesterol," and here's why: these are six different trials with six different groups of people and six different starting points. Zepbound is also a dual GIP/GLP-1 medicine, not a pure GLP-1. Comparing across separate trials is a hint, not a result.

Why do other websites' GLP-1 cholesterol numbers look bigger?

Answer: Most sources report only the treatment group's change from baseline and leave out what happened to the placebo group over the same period. Because placebo groups in weight-loss trials also receive trial visits and lifestyle support, their numbers can improve too. A treatment-only number can be true while still making the medicine's added effect look larger than it was.

We want to show you exactly how this works, using numbers we pulled straight from Novo Nordisk's published STEP 5 trial data. This is the clearest example we found.

Wegovy 2.4 mg — the STEP 5 trial, 104 weeks. Both columns.

The last column is simple arithmetic done by The RX Index from the two published group changes. It is not the trial's adjusted treatment estimate, and rounding can matter. These lipid outcomes were supportive endpoints and were not controlled for multiple testing.³²

Look at the HDL row.

You will see "Wegovy raised HDL 9.6%" repeated across health sites. It's a true treatment-group number. But the placebo group's HDL rose 8.1% over the same two years. Put both columns on the page and the story changes from a 9.6% rise to a simple 1.5-percentage-point gap.

That's not a small presentation choice, and it helps explain why the big pooled analysis we cited earlier found no statistically significant HDL benefit once everything was combined. The two findings can agree. They just look different depending on whether someone shows you the placebo column.

And here's the same check applied to Wegovy HD, using the current label's placebo-relative result:

A site that reports only the first column can honestly write "Wegovy HD lowered LDL 3.5%." A site that shows both columns has to tell you the placebo group lowered it 4.8%, and the FDA label's analysis put Wegovy HD 1.3% above placebo.³²

We're not accusing anyone of lying. We're saying the second version is more useful when the number on your own lab report is the thing you're trying to understand.

The damaging admission, stated plainly

GLP-1 medicines are not LDL drugs. If lowering LDL is your main medical goal, this is the wrong tool, and no honest reading of the data says otherwise.

The Wegovy HD row proves it in the manufacturer's own filing. The highest FDA-approved weekly semaglutide injection dose for weight reduction did not beat placebo on LDL in that trial.

But here's what that leaves room for. These medicines can affect triglycerides, waist size, blood pressure, blood sugar, and inflammation. Those are different jobs from a statin's main LDL-lowering role.

In SELECT, 17,604 adults with established cardiovascular disease, overweight or obesity, and no diabetes received Wegovy 2.4 mg or placebo. Semaglutide reduced major cardiovascular events. A later prespecified analysis found no straight-line link between weight loss at 20 weeks and later events and estimated that about 33% of the benefit was mediated through waist reduction. The authors concluded that mechanisms beyond weight loss were likely involved.⁸

So a flat LDL does not erase Wegovy's proven heart-event benefit in the specific population covered by that approval. It also does not prove the same benefit for every GLP-1, every dose, or every person.

If high LDL is your only problem: close this tab and go have an LDL-treatment conversation with your clinician. That's the right answer, and we'd rather lose you here than pretend otherwise. If you also carry extra weight and want to know whether a GLP-1 would even be covered for you, our guide to GLP-1 insurance coverage for high cholesterol walks through exactly when a plan may say yes.

Compare your own numbers

The averages above tell you what happened to thousands of people. They don't tell you what happened to you.

Copy, print, or screenshot this before your next appointment:

For each lab number:

• Point change = current result − earlier result
• Percent change = (current result − earlier result) ÷ earlier result × 100

A negative change means the number went down. For LDL and triglycerides, that is usually the direction treatment aims for. HDL is different: a higher number can look good, but HDL alone does not settle heart risk.

Do not compare your personal before-and-after percentage directly with the Atlas. Your worksheet has no placebo group. The Atlas numbers are placebo-relative trial estimates. Bring this one-page summary to the clinician who ordered the test so the trend can be read in context.

Which treatment path fits you?

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

One line you should not miss: the branded FDA-label numbers on this page do not prove the same lipid result for a separately compounded medicine. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed.⁹

Before choosing any route, read Is GLP-1 Safe? and GLP-1 Long-Term Side Effects.

Which cholesterol number changes the most on a GLP-1?

Answer: Triglycerides, in the six selected obesity-trial rows examined here. The triglyceride difference was larger than the LDL difference in every row, ranging from 7.1% to 24.9% below placebo. LDL was smaller and inconsistent, ranging from 1.3% above placebo to 5.5% below. HDL rose in the six label rows, but pooled placebo-controlled analysis found no statistically significant HDL benefit across the drug class.

Here's each number, in the order it's likely to matter to you.

Triglycerides — the one that actually moves

This is where the six-row Atlas is most consistent. Every selected row showed a triglyceride drop against placebo, and in most cases a substantial one.

Why can triglycerides move more? Triglycerides often respond to food intake, alcohol, blood sugar, liver fat production, and weight. Several of those can change during GLP-1 treatment.

One honest complication. The pooled analysis of placebo-controlled trials did not find a statistically significant triglyceride reduction across the whole class. That looks like a contradiction with our table. It isn't once you look at which evidence each one includes.

That analysis searched the literature through January 2023 and pooled different medicines, doses, populations, and trial lengths. It could not include the newer 2026 FDA-label trials for Wegovy 25 mg tablets, Wegovy HD 7.2 mg, or Foundayo. Our Atlas uses selected obesity-dose rows instead of estimating one class-wide average.

The honest conclusion is: the size of the triglyceride effect depends heavily on which medicine, dose, population, and trial you are looking at. A pooled class estimate and a selected high-dose obesity trial answer different questions.

We're publishing the disagreement instead of picking whichever version reads better. If a page shows you one and hides the other, ask why.

LDL — the one people care about, and the one that barely budges

Range across the six selected rows: 1.3% higher than placebo to 5.5% lower. Pooled average across placebo-controlled trials: about 3 mg/dL lower.

There is no reading of that data where a GLP-1 is a serious LDL treatment.

HDL — looks great until you check the placebo column

The Atlas shows HDL rising against placebo in every selected row, up to 10.1% for Wegovy HD. Real numbers, from real labels.

But we showed you the STEP 5 breakdown above: +9.6% on the drug, +8.1% on placebo. And the pooled analysis found no statistically significant HDL benefit. Our editorial read: treat HDL as the least reliable good-news number in this whole conversation. A rising HDL is nice. It does not tell you your heart risk is handled.

Total cholesterol — the number that hides things

Total cholesterol adds several lipid values together. That's the problem. If your LDL rose and your HDL rose, your total can look "worse" while the underlying picture is mixed. If your triglycerides crashed and your LDL didn't move, your total looks better than your LDL story deserves.

Never judge a GLP-1 by total cholesterol alone.

Non-HDL, ApoB, and Lp(a) — worth knowing about

Three markers your standard panel might not show:

• Non-HDL cholesterol. Total minus HDL. Useful when your triglycerides are high, because standard LDL is often calculated rather than measured, and very high triglycerides can make that calculation less reliable.
• ApoB (apolipoprotein B). Counts the cholesterol-carrying particles that can get into an artery wall. Sometimes tells a different story than LDL.
• Lp(a) (lipoprotein little-a). A largely inherited risk marker that a normal lipid panel doesn't measure at all.

The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once in adulthood and supports checking ApoB selectively — including for people with diabetes, triglycerides above 200 mg/dL, existing cardiovascular disease, or LDL already below 70 mg/dL.⁷

This is not a "go order every test" recommendation. It's a "these exist, and they may be worth asking about" one.

Why did my cholesterol go UP even though I lost weight?

Answer: A higher cholesterol result during active weight loss does not automatically mean the medicine caused it or that your progress failed. Testing conditions, medication changes, starting values, illness, diet, genetics, and where you are in your weight loss can all affect a single panel. One small study documented a temporary rise in serum cholesterol during major weight loss that resolved after weight stabilized, but it was not a GLP-1 study.

This is the question that brings most people to this page, and it's the one that gets answered worst everywhere else. Let's take it seriously.

First — you're not imagining it, and you're not alone

Here's how one person described it in a public forum after losing 70 pounds and getting a higher cholesterol result:

"This feels like getting an F on a test even though I got all the answers right."

(Patient language from a public discussion thread, r/Ozempic. We include it to show you the feeling is common. It is not medical evidence and it is not a testimonial.)¹⁰

That reaction makes complete sense. You did the hard thing. The number went the wrong way. Now let's look at why that can happen.

One documented pattern: a temporary rise during major weight loss

In a study published in the American Journal of Clinical Nutrition, six women lost an average of about 30 kg on a very-low-calorie diet. Their total cholesterol dropped sharply at first. Then — while they were still losing weight — it climbed back up past where it started. Once their weight held steady for at least two months, it came back down. The researchers also biopsied abdominal fat and found that its cholesterol content had gone up during the weight-loss phase.¹¹

The researchers said the temporary rise was possibly caused by cholesterol moving out of fat stores. They did not prove that mechanism.

Now the limits, because they matter. That study had six participants. It was published in 1991. It used a very-low-calorie diet, not a GLP-1. It describes a pattern that can happen during major weight loss — it is not evidence about GLP-1 medicines specifically.

We're telling you about it because it is the best directly measured example we found for a pattern people report, and because we'd rather show you a small old study honestly than pretend we have a big new one. It is something to raise with your prescriber, not a conclusion you should reach on your own.

There's a related clue in newer tirzepatide data. In a post-hoc conference abstract from SURMOUNT-1 and SURMOUNT-2, roughly 69% to 85% of the changes in total cholesterol, HDL, LDL, and non-HDL at 24 weeks in SURMOUNT-1 were classified as unassociated with weight reduction. For VLDL and triglycerides, the share was 41% to 43%. By 72 weeks, most changes were more closely tied to weight reduction.¹²

That was a post-hoc model reported in a conference abstract, not a trial built to explain your result. The useful point is narrower: the relationship between weight loss and each lipid marker can change over time, and the markers do not all behave the same way.

Second — check whether your two tests are even comparable

Before you conclude anything, run through this list. Any one of these can move a number or change how it should be read:

• Were both draws fasting, both nonfasting, or different?
• Was it the same lab both times?
• Were you sick near either draw?
• Did any medication start, stop, or change dose — especially a statin?
• Did you miss doses of a cholesterol medicine?
• Is your weight still dropping, or has it settled?
• Did your diet or alcohol use change in a big way?
• Was LDL measured directly, or calculated from the other numbers?

These are things to review, not causes we've proven for you.

Third — what not to do

• Don't stop your statin. Not because your weight is down. Not because one number improved.
• Don't stop your GLP-1 because one number went up.
• Don't change a dose on your own.
• Don't assume a story you read online explains your result. Including this one.
• Don't dismiss a very high number because your weight improved.

Numbers that mean call your clinician promptly

Two results should not be interpreted from a web page:

• LDL at or above 190 mg/dL
• Triglycerides at or above 500 mg/dL

Current cardiovascular guidance flags both levels for evaluation. A triglyceride level of 500 mg/dL or higher also raises concern for pancreatitis risk. If a nonfasting triglyceride result is 400 mg/dL or higher, a fasting repeat is generally recommended so triglycerides and baseline LDL can be assessed more reliably.⁷

These aren't automatic emergency-room thresholds. They mean: contact whoever ordered the test, promptly, and get individual guidance. Severe symptoms still deserve urgent care on their own.

→ Jump back to the one-page lab summary

Put both test dates, your fasting status, your medicines, and your marker-by-marker results into the worksheet. It organizes the facts without claiming to know what caused the change. Most appointments are short. This is how you use them well.

Can a GLP-1 replace my statin?

Answer: No. The 2026 ACC/AHA dyslipidemia guideline continues to treat statins as the foundation of LDL lowering when medication is needed. High-intensity statins lower LDL by 50% or more; GLP-1 medicines lowered LDL by about 3 mg/dL on average in pooled placebo-controlled trials. Decisions about stopping or reducing a statin belong to the prescriber who ordered it.

These two drug types are not competing for the same job. Here's the side-by-side.

What "heart benefit" does and doesn't mean

Wegovy has an FDA indication for reducing major cardiovascular events in adults with existing heart disease plus overweight or obesity. That is a real, specific approval — and it is not the same as being approved to treat cholesterol.³

A medicine can lower heart-attack risk through several pathways at once without being an LDL drug. That's what SELECT suggests happened: the benefit was independent of weight loss, with only about a third estimated to be mediated through waist reduction.⁸

So don't let a heart-risk benefit become permission to stop an LDL treatment. Different mechanisms, different jobs.

About taking both at once

Many people take a GLP-1 and a statin together. That can be appropriate. But we won't tell you it's universally fine, because the exact products matter.

One concrete exception: Foundayo's prescribing information says active simvastatin exposure increased about two- to 2.5-fold and says simvastatin should not exceed 20 mg daily when used with Foundayo. The same label found no clinically relevant exposure changes for atorvastatin or rosuvastatin.⁶

That's precisely why "GLP-1s don't interact with statins" is too broad a statement to make. Ask your pharmacist or prescriber. Bring the exact drug names and doses.

Seven questions to bring to your appointment

1. What LDL or non-HDL number are we aiming for in my case?
2. Are my baseline and current tests actually comparable?
3. Was this panel fasting, and did it need to be?
4. Could any other medicine have affected these results?
5. Should we look at ApoB or Lp(a)?
6. When should I repeat this panel?
7. What would make you change either of my medicines?

What target applies to you

The 2026 ACC/AHA guideline sets goals by risk level rather than one number for everyone. Broadly: below 100 mg/dL for many people at borderline or intermediate risk without existing heart disease, below 70 for high-risk primary-prevention patients, and below 55 for very-high-risk people with established atherosclerotic cardiovascular disease.⁷

Those are guideline categories, not your personal target. Which one applies to you depends on your full risk picture, and that's a conversation, not a lookup.

Which GLP-1 is best for cholesterol?

Answer: No single medicine can be named best for cholesterol from the available evidence, because the six Atlas rows were not head-to-head. In those selected FDA-label trials, Zepbound 15 mg showed the largest numerical improvements in LDL and triglycerides — but tirzepatide is a dual GIP/GLP-1 medicine studied in a different trial population, and cholesterol is not its approved treatment purpose.

We know that's not the crisp answer you wanted. Here's why we won't give you a crisper one.

Why the Atlas isn't a ranking

Six rows, six separate trials. Different participants. Different starting cholesterol. Different trial lengths. Different statistical methods for handling people who dropped out. Different background medications.

Line those up in a table and your eye reads it as a leaderboard. It isn't one. It's six independent measurements that happen to share a format.

Correct way to say it: In these selected obesity trials, Zepbound 15 mg showed larger numerical triglyceride and LDL differences than the selected semaglutide rows.

Wrong way to say it: Zepbound is proven best for cholesterol.

What a 2026 research ranking found

A 2026 network meta-analysis pulled together 19 randomized trials covering 13,117 participants and built a combined score from seven outcomes — weight, waist, blood sugar, blood pressure, LDL, HDL, and triglycerides. Among the selective GLP-1 medicines it evaluated, semaglutide 7.2 mg ranked highest, followed by orforglipron and semaglutide 2.4 mg.¹³

Interesting. But it does not answer your question, for three reasons:

1. It's a composite. Seven outcomes rolled into one score. A drug can rank first overall while performing poorly on one specific marker.
2. It excluded tirzepatide because it studied selective GLP-1 medicines only — leaving out the drug with the largest numbers in our Atlas.
3. It's a research ranking, not a treatment tool. It wasn't built to pick a medicine for an individual.

And the Wegovy HD row is the perfect illustration of problem #1. Semaglutide 7.2 mg tops that composite ranking — and it's the one row in our Atlas where LDL didn't improve against placebo. Strong overall, weak on that one marker. A composite score would never show you that. A drug-by-drug table does.

SURMOUNT-5 did compare tirzepatide with semaglutide head to head for obesity, but it was designed around weight loss, not to prove which medicine is best for cholesterol.¹⁴

Our actual editorial judgment

Based on the verified data on this page, and labeled clearly as our conclusion rather than a proven fact:

If triglycerides are your problem, which medicine you take probably matters. The spread in the Atlas runs from −7.1% to −24.9%. That's a real difference.

If LDL is your problem, which GLP-1 you take probably doesn't matter much, because none of them do the job. The spread is +1.3% to −5.5%, and a statin operates in a completely different range.

That's the most useful thing we can honestly tell you.

How long until my cholesterol changes on a GLP-1?

Answer: The lipid results in the selected FDA-label trials were measured after 56 to 72 weeks of treatment — well over a year. Changes may appear earlier, but there is no universal GLP-1-specific schedule for repeat lipid testing. The commonly cited 4-to-12-week recheck window applies to starting or changing LDL-lowering therapy, not automatically to every GLP-1 start.

Every number in the Atlas came from a trial endpoint between 56 and 72 weeks. That's the honest time frame for those exact numbers.

We won't give you a made-up testing schedule. When you retest depends on why the test was ordered, how high the result was, whether a statin or another medicine changed, and what your clinician is monitoring.

Routine cholesterol testing does not always require fasting. Follow the lab or ordering clinician's instructions. When you compare two panels, using the same lab and similar fasting conditions can make the comparison cleaner, especially for triglycerides and calculated LDL.

What happens to my cholesterol if I stop?

Answer: In the exploratory STEP 1 extension, 327 participants who stopped semaglutide regained about two-thirds of their prior weight loss within one year, and many cardiometabolic measures moved back toward baseline. One year off treatment, triglycerides, HDL, VLDL, and CRP still favored the former semaglutide group compared with placebo. LDL and total cholesterol were not among the markers the paper said remained improved.

That last sentence is the interesting part, and we haven't seen it written anywhere else.

The extension was small and exploratory. It followed 327 people from a much larger trial, and some participants used other weight-management medicines during follow-up. It does not tell us what every GLP-1 product does after stopping.¹⁵

Look at which numbers still favored the former semaglutide group a year off the drug: triglycerides, HDL, VLDL, and CRP, an inflammation marker. LDL and total cholesterol weren't on the list.

The story is internally consistent with the stronger pattern in the Atlas. Triglyceride-related markers showed the clearer signal. LDL and total cholesterol did not.

The weight data is blunt: about two-thirds of the prior loss was regained in twelve months. If you're thinking of this as a short course to reset your labs, the published evidence doesn't support that plan.

Do better cholesterol numbers explain the heart benefits?

Answer: Not on their own. In a prespecified analysis of SELECT's 17,604 participants, semaglutide's cardiovascular benefit was independent of baseline body size and weight loss, with roughly 33% of the benefit estimated to be mediated through waist circumference reduction. Improving a lab marker is not the same as reducing events.

Two words worth separating:

• A marker is a number, like LDL.
• An outcome is a thing that happens to a person, like a heart attack.

Improving a marker can predict better outcomes. It does not guarantee them, and the size of the marker change doesn't always match the size of the outcome benefit.

SELECT is the cleanest example. Semaglutide reduced major cardiovascular events in adults with established cardiovascular disease, overweight or obesity, and no diabetes. The lipid changes in the obesity trials are small. The prespecified analysis found no straight-line link between early weight loss and later events and pointed to mechanisms beyond weight loss alone.⁸

What this means for you, practically: if your LDL barely moved on Wegovy, that is not evidence the medicine isn't helping your heart when you fit its cardiovascular indication. It also does not mean LDL can be ignored or that a statin should be stopped.

One caution the other direction: a heart-event indication belongs to a specific product for a specific population. It is not a class-wide feature. Don't assume the drug you're on carries it.

Who should be watching these numbers with you?

Answer: Every number on this page only means something if someone is measuring it and interpreting it in the context of your full health picture. That requires a prescriber who reviews results and can adjust your plan. Telehealth programs differ on whether they order lab work, what is included, and who follows up on an abnormal result.

This is the practical gap we run into constantly at The RX Index. People start a GLP-1 through a program that never makes the lab plan clear, then find themselves googling their results with no one to ask.

If you've read this far, you're clearly the kind of person who wants the numbers. Confirm these four things before paying:

1. Who orders the lab, and when?
2. Is the lab included or billed separately?
3. Who reviews an abnormal result?
4. Can the clinician manage both the GLP-1 and a cholesterol medicine, or will you need another prescriber?

That four-question check is more useful than a generic promise of "ongoing support."

If you want a program that can order labs and handle insurance paperwork

Ro is the one sponsored placement on this page. Its public terms say a Ro-affiliated clinician can order lab testing when needed and that provider-ordered testing is included in the base membership. Extra tests may carry a separate fee. Its insurance route currently lists Wegovy pen, Zepbound autoinjector, and Ozempic.¹⁶¹⁷¹⁸

Ro Body pricing and terms, verified August 8, 2026

This verifies what Ro publicly states. It does not independently test care quality, response time, coverage success, or clinical outcomes.

Two things we'd want to know first. Ro does not bundle your medication into the membership price — it's two separate bills. The lowest membership rate also requires paying for a year upfront, and membership fees are nonrefundable after enrollment. If a single all-in monthly price with no surprises is what you want, Ro is the wrong fit. But its team can handle benefits checks and prior-authorization paperwork for the products its insurance route supports. That's the trade.

Ro's terms also allow compounded medication during national shortages. The FDA-label lipid data on this page must not be treated as evidence for any compounded prescription offered through Ro or another provider.⁹¹⁸

Check current Ro eligibility and pricing → (sponsored)

If you're on Medicaid, start with our coverage guide instead — the path is different.

Not sure which fits? Find My GLP-1 Path sorts it by your state, your insurance, and your budget in about two minutes.

What we actually verified

We think you should be able to check our work. Here's exactly what we did and where we came up short.

What we checked on August 8, 2026:

• Four current U.S. prescribing-information documents covering six selected trial rows: Saxenda, Wegovy 2.4 mg injection, Wegovy 25 mg tablet, Wegovy HD 7.2 mg, Foundayo, and Zepbound. For each row, we recorded the label's placebo-relative percentage for total cholesterol, LDL, HDL, and triglycerides.³⁴⁵⁶
• Novo Nordisk's published STEP 5 and STEP UP data, recording both the treatment column and the placebo column. We labeled our simple subtraction as arithmetic, not an adjusted treatment estimate. That side-by-side calculation is original analysis on this page.²
• The pooled GLP-1 meta-analysis for the class-wide figures in mg/dL.¹
• The STEP 1 trial extension for what happened after semaglutide withdrawal.¹⁵
• The prespecified SELECT analysis for how cardiovascular benefit related to weight and waist change.⁸
• The 1991 study on temporary hypercholesterolemia during major weight loss.¹¹
• The 2026 ACC/AHA dyslipidemia guideline for statins, LDL goals, Lp(a), ApoB, fasting, and prompt follow-up thresholds.⁷
• The 2026 network meta-analysis and the post-hoc SURMOUNT lipid analysis.¹³¹²
• Ro's public pricing, insurance, and program-terms pages.¹⁶¹⁷¹⁸

What we could not verify:

• In our August 8, 2026 search, we found no product-specific, peer-reviewed lipid-outcome trial for a compounded semaglutide or tirzepatide prescription. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing.⁹ Every label figure on this page belongs to an FDA-approved product and should not be applied to a separately compounded one.
• We could not independently verify what any individual reader's lab change means. That requires the clinician who knows the test conditions, medicines, and full risk picture.

What this page is not: medical advice, a diagnosis, or a substitute for the clinician who prescribes for you.

Frequently asked questions

Does Ozempic lower cholesterol? Semaglutide can produce modest lipid changes, but Ozempic's approved purpose is type 2 diabetes, not treating high cholesterol. Don't apply Wegovy's obesity-trial percentages to Ozempic — different dose, different trial population, different label. Check Ozempic's own prescribing information for product-specific numbers.

Does Wegovy lower LDL cholesterol? It depends on the formulation and dose. In the selected 2.4 mg injection trial, LDL was 3.8% below placebo, and in the 25 mg tablet trial it was 3.1% below. In the Wegovy HD 7.2 mg trial, LDL was 1.3% above placebo. Same molecule, three different answers.

Does Wegovy lower triglycerides? Yes, in all three selected Wegovy formulation rows — roughly 9.9% to 15.8% below placebo depending on the formulation and trial. That's a trial average, not a promise about your result.

Does Zepbound lower cholesterol? In the selected 15 mg obesity trial, total cholesterol was 4.6% below placebo, LDL 5.5% below, HDL 8.7% above, and triglycerides 24.9% below. Those are the largest numbers in our comparison. Zepbound is not approved as a cholesterol treatment.

Can a GLP-1 raise LDL? An individual's LDL can rise, and in one current label comparison — Wegovy HD — the treatment group's LDL was 1.3% higher than placebo. That doesn't prove what will happen to you or explain why your own number moved.

Why did my triglycerides improve but my LDL didn't? Those two markers reflect different parts of how your body handles fat and cholesterol, and they don't have to move together. The Wegovy HD row is the clearest published example in our Atlas: triglycerides 15.4% below placebo, LDL 1.3% above.

Can I take a GLP-1 and a statin at the same time? Often yes, and many treatment plans include both. But the specific drugs, doses, and your health history need review by your prescriber or pharmacist. Foundayo has a specific simvastatin limit in its FDA label.

Can I stop my statin after losing weight on a GLP-1? Not on your own, and not because of one improved lab result. Your prescriber weighs the trend, your target, and your overall cardiovascular risk. Weight loss alone doesn't make that call.

Which is better for cholesterol, semaglutide or tirzepatide? The six separate label trials cannot settle it. Tirzepatide showed larger numbers in our selected comparison, but it is a dual GIP/GLP-1 medicine studied in a different trial. SURMOUNT-5 compared the drugs head to head for obesity, but it was not designed to prove which is best specifically for cholesterol.¹⁴

How often should I check my cholesterol on a GLP-1? There's no universal GLP-1-specific interval. Timing depends on your starting result, whether a statin or another medicine changed, and why you're being monitored. Ask whoever ordered the test.

Do I need to fast for a cholesterol test while taking a GLP-1? Not always. A routine lipid panel can often be done without fasting. A nonfasting triglyceride result at or above 400 mg/dL should generally be repeated fasting. Follow the instructions from the lab or ordering clinician.⁷

Does compounded semaglutide affect cholesterol the same way? We found no product-specific, peer-reviewed lipid-outcome trial for a compounded semaglutide or tirzepatide prescription in our August 8, 2026 search. Branded prescribing-information results cannot be presented as evidence for a separately compounded medicine, and we won't do it.⁹

Is ApoB more useful than LDL? LDL remains a main treatment target. ApoB can add information when particle count and LDL tell different stories — particularly for people with diabetes, triglycerides above 200 mg/dL, existing cardiovascular disease, or LDL already below 70 mg/dL. The 2026 guideline supports using it selectively rather than routinely.⁷

Will insurance cover a GLP-1 because of high cholesterol? Usually not on its own. Weight, diabetes, established heart disease, sleep apnea, liver disease, the exact product, and your specific plan rules can all change the answer. Our coverage guide walks through each scenario.

The bottom line

GLP-1 medicines change your cholesterol numbers. Just not the way most of the internet implies.

Triglycerides are the number that moves in the six selected obesity-label rows — 7.1% to 24.9% below placebo, and the largest lipid difference in every row we examined.

LDL barely moves. About 3 mg/dL lower on average in the pooled placebo-controlled analysis. In the Wegovy HD trial, the highest FDA-approved weekly semaglutide injection dose for weight reduction did not beat placebo on LDL.

HDL looks better than it is once you notice how much the placebo group also changed in STEP 5.

None of this makes a GLP-1 a cholesterol drug, and none of it replaces a statin.

And if your LDL didn't budge — that isn't proof of failure. In SELECT, Wegovy's heart benefit in its specific trial population was independent of weight loss. Your lipid panel does not measure every pathway that can change cardiovascular risk.

Bring your actual numbers, your fasting status, and your medicine list to the person who prescribes for you. That's what turns a confusing lab result into a real decision.

Still not sure which GLP-1 program is right for you? Take our free two-minute matching quiz. No signup required.

Who wrote this and how

Who: The RX Index Editorial Team.

How: We opened four current U.S. prescribing-information documents covering six selected trial rows and pulled the lipid outcomes into a single standardized table. We recorded both treatment and placebo columns where the manufacturer published them and labeled our own subtraction as simple arithmetic rather than an adjusted drug effect. We compared those label results against a pooled meta-analysis and the 2026 ACC/AHA dyslipidemia guideline, and published the places where they disagree instead of choosing one.

Why: People are told constantly that GLP-1 medicines "improve cholesterol," without ever being shown which number changed, by how much, or how inconsistent the results are. Then their own lab report doesn't match the story, and there's nowhere good to look. This page exists to close that gap without pretending a GLP-1 is a cholesterol drug.

Update log August 8, 2026 — First published. Added current FDA-label lipid data for Saxenda, Wegovy 2.4 mg injection, Wegovy 25 mg tablet, Wegovy HD 7.2 mg, Foundayo, and Zepbound; standardized six trial rows; added treatment-versus-placebo columns; verified the 2026 dyslipidemia guideline and Ro terms.

Sources

1. Rivera FB, Chin MNC, Pine PLS, et al. Glucagon-like peptide 1 receptor agonists modestly reduced LDL and total cholesterol independent of weight reduction: a meta-analysis and meta-regression. Current Medical Research and Opinion. 2025;41(1):185–197. PMID 39666879.
2. Novo Nordisk. Wegovy chronic weight-management trial results, including STEP 5 and STEP UP lipid columns. Accessed August 8, 2026.
3. U.S. Food and Drug Administration. Wegovy prescribing information, revised June 2026.
4. U.S. Food and Drug Administration. Saxenda prescribing information, 2026.
5. U.S. Food and Drug Administration. Zepbound prescribing information, revised February 2026.
6. U.S. Food and Drug Administration. Foundayo prescribing information, 2026.
7. American College of Cardiology and American Heart Association. 2026 Guideline on the Management of Dyslipidemia. Published March 13, 2026.
8. Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified SELECT analysis. The Lancet. 2025. PMID 41138739.
9. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Accessed August 8, 2026.
10. Reddit, r/Ozempic. “70 lbs lost but cholesterol went up. Why?”. Accessed August 8, 2026. Patient language only; not medical evidence.
11. Phinney SD, Tang AB, Waggoner CR, et al. The transient hypercholesterolemia of major weight loss. American Journal of Clinical Nutrition. 1991;53(6):1404–1410.
12. Linetzky B, et al. Body-weight-reduction-associated and unassociated changes in lipid profile with tirzepatide: post-hoc SURMOUNT-1 and SURMOUNT-2 analysis. Circulation. Conference abstract 4141358.
13. Lu Y, Chen J, Guo Y, et al. Cardiometabolic profiles of oral and subcutaneous GLP-1 receptor mono-agonists in adults with overweight or obesity: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism. 2026;28(7):5761–5766. PMID 41992023.
14. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025. PMID 40353578.
15. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564. PMID 35441470.
16. Ro. Ro Body program pricing. Accessed August 8, 2026.
17. Ro. Ro Body insurance information. Accessed August 8, 2026.
18. Ro. Terms of Use, Ro Body Program. Accessed August 8, 2026.